Emcure Pharmaceuticals Ltd.
EMCURE · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,012.82.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%19.6%
- ✓Low debt (D/E < 0.5)0.31x
- ✓Positive free cash flow
- ✓Revenue growth > 10%17%
- ✓Earnings growing29%
- ✓Net margin ≥ 10%10.0%
- ✕Current ratio > 1.51.43
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 5.84
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (19.6%).
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 5.84.
Opportunities
- •Earnings growing (29% YoY).
- •Revenue growing (17% YoY).
- •Trading in our value buy zone versus sector peers.
Threats
- •Trades ~26% above our estimated fair value.
About Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.